Kairos Pharma to Present at D. Boral Capital Global Conference, Showcasing Oncology Research
TL;DR
Kairos Pharma (NYSE American: KAPA) will showcase at the D. Boral Capital Global Conference, enhancing investor visibility.
Kairos Pharma focuses on oncology therapeutics, using ENV105 to target CD105 and reverse drug resistance in cancer treatment.
Kairos Pharma's ENV105 aims to improve cancer treatment effectiveness, addressing significant unmet medical needs and enhancing patient outcomes.
Kairos Pharma's participation in the D. Boral Capital Global Conference presents a unique opportunity for investors to engage with CEO John Yu, MD.
Found this article helpful?
Share it with your network and spread the knowledge!
Kairos Pharma Ltd., a biotechnology company focused on oncology therapeutics, will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025. CEO and Chairman John Yu, MD, will engage in one-on-one meetings with investors at The Plaza Hotel in New York City.
The conference provides a critical platform for Kairos Pharma to discuss its pioneering research in overcoming cancer treatment challenges. The company's lead candidate, ENV105, represents a significant advancement in addressing drug resistance in cancer therapies. By targeting CD105, a protein that drives treatment resistance, ENV105 aims to restore the effectiveness of standard cancer treatments.
Currently, ENV105 is undergoing clinical trials in two critical areas: a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. These trials target significant unmet medical needs in oncology, potentially offering new hope for patients experiencing treatment resistance.
The conference presentation represents an important opportunity for Kairos Pharma to communicate its scientific approach and potential breakthrough in cancer treatment to potential investors and industry stakeholders. By utilizing structural biology to combat drug resistance and immune suppression, the company is positioning itself at the forefront of innovative oncological research.
Curated from InvestorBrandNetwork (IBN)
